Avid Bioservices Inc (CDMO)

[NoMoDo]

from insider financial:

As of February 1, 2016, Avid Bioservices had a revenue backlog in excess of $58 million under committed contracts from existing clients. In addition, Peregrine had $67.5 million in cash and equivalents as of January 31, 2016.

I think $25mil a quarter is realistic and the quote above points to the same conclusion. Should that happen, dilution could be a thing of the past.